An elderly woman with triple primary metachronous malignancy: A case report and review of literature  by Takalkar, Unmesh et al.
A
c
U
B
a
b
c
A
R
R
A
A
K
M
A
I
P
1
t
t
o
r
a
t
i
t
i
t
A
2
hCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 4 (2013) 593– 596
Contents lists available at SciVerse ScienceDirect
International  Journal  of  Surgery  Case  Reports
journa l h om epage: www.elsev ier .com/ locate / i j scr
n  elderly  woman  with  triple  primary  metachronous  malignancy:  A
ase  report  and  review  of  literature
nmesh  Takalkara, Balaji  N.  Asegaonkara, Pushpa  Kodlikeri a,  Shilpa  Asegaonkarb,∗,
rijmohan  Sharmaa,  Suresh  H.  Advania,c
Kodlikeri Memorial Hospital & CIIGMA Hospital, Aurangabad 431005, India
Government Medical College, Aurangabad, India
Asian Institute of Oncology, S.L. Raheja Hospital, Raheja Hospital Road, Mahim, Mumbai 400016, India
a  r  t  i  c  l e  i  n  f  o
rticle history:
eceived 17 November 2012
eceived in revised form 19 March 2013
ccepted 24 March 2013
vailable online 4 April 2013
eywords:
ultiple primary malignancies
denocarcinoma  of small intestine
nﬁltrating duct carcinoma of breast
apillary adenocarcinoma of ovary
a  b  s  t  r  a  c  t
INTRODUCTION:  Prevalence  of  multiple  primary  malignancies  is  slowly  increasing  due  to  prolonged  sur-
vival  of  cancer  patients  with  advances  in diagnostic  and  therapeutic  modalities.  The  reasons  may  be
environmental  modiﬁcations,  genetic  predisposition  or therapy  induced.  We  describe  a  case  of  a  64-
year-old  woman  with  three  different  metachronous  primary  malignancies  managed  at  our  center  since
4  years.
PRESENTATION  OF  CASE:  First primary  diagnosed  in  our  patient  was  adenocarcinoma  of  small  intes-
tine  which  is  a rare  gastrointestinal  malignancy.  For  this  she  underwent  surgical  resection  followed  by
chemotherapy.  After 21  months  she  developed  inﬁltrating  duct  carcinoma  of breast  which was  managed
with  modiﬁed  radical  mastectomy  and  chemotherapy.  Again  after  latent  period  of  10 months  patient
had  papillary  adenocarcinoma  of ovary  for which  she  was  administered  chemotherapy.  During  follow
up  tumor  was  found  to  be chemoresistant  and  again  she  underwent  cytoreductive  surgery  followed  by
chemotherapy.
DISCUSSION:  In present  case  patient  did  not  have  signiﬁcant  risk  factors  for development  of  carcinoma  of
small  intestine,  breast  and  ovary.  Our patient  underwent  surgical  excision  three  times  and  received  total
16  chemotherapy  cycles  of different  regimens  during  management  of all three  primary  malignancies.
Development  of  second  and  higher  order  primary  malignancy  after  successful  management  of previous
one  should  be  always  kept  in  mind.
CONCLUSION: Awareness,  suspicion  of multiple  primary  malignancy  and  aggressive  diagnostic  work  up
plays  crucial  role in  their  detection  at earlier  stage  for  better  outcome.  In  addition  choice  of  appropriate
chemotherapeutic  agents  and  their  regimens  remains  the  cornerstone  while  managing  the  patients  with
multiple  primary  malignancies.
gical © 2013 Sur
. Introduction
Multiple primary malignancy (MPM)  is deﬁned as occurrence of
wo or more malignancies in the same individual without any rela-
ionship between the tumors either simultaneously or with interval
f time. MPM  in the same individual was ﬁrst described by War-
en and Gals. Although rare, its reported incidence in clinical and
utopsy cases varies from 3 to 5% of all malignancies among which
riple tumors are seen in 0.5% of cases.1 Number of cancer survivors
s growing by 2% each year with advances in diagnostic modalities,
reatment and supportive care.2 An individual may  develop MPM
n lifetime due to genetic predisposition, environmental exposure
o carcinogens, immunodeﬁciency or as a serious complication of
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chemotherapy or radiotherapy received for ﬁrst primary malig-
nancy. National Cancer Institute’s Surveillance, Epidemiology, and
End Results Program reported that about one in six cancer patients
develop second malignant neoplasm in their further lifetime.3
In literature several interesting cases of MPM  involving differ-
ent organs have been reported. But as per our knowledge after
extensive search in literature, the case described herein is the ﬁrst
report of triple primary metachronous malignancy involving small
intestine, breast and ovary in a postmenopausal woman  from India.
2. Presentation of a case
A  64-year-old Indian woman  with triple primary malignancy
of small bowel followed by carcinoma of breast and then of ovary
Open access under CC BY-NC-ND license. over last four years was  managed successfully at our center. On
acquisition of detailed medical history, there was no personal or
family history of cancer as well as major risk factor for cancer. She is
multiparious woman  with age of menarche at 14 years and parity at
Y-NC-ND license. 
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hematological, lung, thyroid, breast, skin and genitourinary
malignancies.6 In present case ﬁrst primary malignancy was ade-
nocarcinoma of small intestine which is a rare condition accounting
for 0.1 to 0.3% of all and 2% of gastrointestinal malignancies.7 TheFig. 1. Specimen of resected small intestine with growth in terminal ileum.
1 year. She is menopausal with her last period about 20 years ago.
ur patient never received hormone replacement therapy and oral
ontraceptive pills in her lifetime. She is known to be hypertensive
ince ten years controlled with antihypertensive drugs.
In  July 2009 patient presented with two-month history of vague
bdominal pain. Abdominal ultrasound and computer tomogra-
hy provided a clue suggestive of small bowel tumor of size
 × 3 cm.  Laboratory parameters were within normal limit. Explo-
ative laparotomy revealed an evidence of intestinal obstruction
ue to stricture with growth at terminal ileum (Fig. 1). So tumor was
xcised with end to end anastomosis. There was no evidence of any
elvic mass. Histopathology revealed moderately differentiated
denocarcinoma of ileum of stage III (T2N1M0) with evidence of
etastasis in mesenteric lymph nodes. Then she received six cycles
f adjuvant chemotherapy of regimen Taxenes 260 mg  (Paclitaxol),
arboplatin 450 mg  every 21 days. Any chemotherapy induced seri-
us adverse events were not reported during and after completion
f chemotherapy. This management ceased the progression of dis-
ase.
In April 2011 patient complained of lump in right breast. Phys-
cal examination conﬁrmed a palpable mass of size 4 cm × 3 cm
n upper outer quadrant without evidence of nipple discharge
nd ulceration. Fine needle aspiration cytology revealed presence
f malignant cells and patient underwent modiﬁed radical mas-
ectomy with axillary lymph node dissection. On macroscopic
xamination size of tumor was 4 cm × 3 cm × 3 cm.  Histologically
t was well differentiated inﬁltrated duct carcinoma showing pres-
nce of large cells with hyper chromatic pleomorphic nuclei,
itotic ﬁgures, nucleoli and scanty cytoplasm (Fig. 2). As per Scarf
loom scoring system it was grade II tumor. All 9 lymph nodes from
evel I and II and 3 from level III were free of metastasis. On immuno-
istochemistry, estrogen receptors were positive in 90% tumor cells
ith Allred score 8/8. Progesterone receptors were positive in 40%
umor cells with Allred score 6/8. Tumor was negative for Cerb B2
xamination. There was no evidence of distant metastasis at that
ime. Patient received six cycles of adjuvant chemotherapy with
yclophosphamide 750 mg,  Epirubicin 110 mg  and 5-ﬂuorouracil
50 mg,  on every 21 days. After six months she developed type 2
iabetes mellitus and managed with oral hypoglycemic drugs.
In  February 2012, patient complained of pain and bloating sen-
ation in abdomen. Abdominal ultrasound examination revealed
ilateral large solid and cystic lesion of size 27 × 15 cm in pelvic
egion with evidence of ascites and bilateral pleural effusion. Her
erum CA 125 was found to be raised to 79.7 U/ml. Ultrasound
uided ﬁne needle aspiration cytology showed presence of malig-
ant cells suggesting well differentiated adenocarcinoma of ovary.
ecause of presence of ascites and large size of tumor she started
ith chemotherapy regimen of gemcetamine and carboplatin fol-
owed by assessment of response to this therapy. Her serum CA 125
as found to be raised to 239.7 U/ml and because of chemoresistantFig. 2. Histopathological features of inﬁltrated duct carcinoma of breast.
nature of tumor surgeon felt she should be considered for surgi-
cal excision of tumor (Fig. 3). Histopathologically it was papillary
adenocarcinoma of ovary of grade IV comprised of papillary and
gland like structures formed by large cuboidal to columnar cells
with large hyper chromatic pleomorphic nuclei and scanty cyto-
plasm (Fig. 4). Cytoreductive surgical management will improve
outcome of patient and response to chemotherapy.
During this period all vital signs and laboratory workup includ-
ing hematological, renal and liver function tests were within
normal limit. Our patient tolerated her treatment with minimal
side effects and without complications.
3. Discussion
MPM  are categorized into two  types (a) synchronous have all
malignant lesions at the same time or within six months of ﬁrst
malignancy (b) metachronous in which second or high order malig-
nancies follows in sequence at least six months after previous one.4
Cancer survivors have 20% higher risk of new primary cancer
in same or different organ in comparison with general population.
Second and higher ordered primary cancers can be therapy induced,
syndrome related or by sharing common etiologic factors.5
Multiple metachronous malignancies are often seen withFig. 3. Resected specimen of tumor of ovary.
CASE  REPORT  –  O
U. Takalkar et al. / International Journal of S
p
h
i
o
l
d
o
1
a
p
i
c
m
b
m
c
r
o
t
o
o
S
p
N
e
c
b
t
t
a
i
o
r
c
g
a
7.  Varghese R, Weedon R. ‘Metachronous’ adenocarcinoma of the small intestine.Fig. 4. Histopathological features of papillary adenocarcinoma of ovary.
atients with familial adenomatous polyposis, Crohn’s disease or
ereditary nonpolyposis colorectal carcinoma are known to have
ncreased risk of primary adenocarcinoma of small intestine.8 But
ur patient did not have any such predisposing factor. As per the
iterature most common site of malignancy in small intestine is
uodenum. Brucher et al. found no patient with adenocarcinoma
f the ileum in their series.9 Recently, Dabaja et al., reported a
3% incidence of adenocarcinoma in the ileum.10 Sook Hee Hong
nd colleagues in their retrospective analysis for 53 patients with
rimary adenocarcinoma of small intestine reported recurrence
n 13 of 26 patients after curative resection but not a single
ase of MPM.11 Amin et al. documented evidence of one third
etachronous cancers in patients with small intestine malignancy,
ut in carcinoid syndromes.12 Antal et al. reported triple primary
alignancies in four of 719 cancer patients but involving different
ombinations of organs.13
Higher incidence of MPM  has been observed in embryologically
elated organs endometrium and ovary. Most frequently involved
rgan in MPM  is breast due to embryological and hormonal fac-
ors. Familial carcinoma syndrome is a combination of carcinoma
f breast and ovary. But our patient does not have family history
f cancer and also no known risk factor for these malignancies.
o present case is sporadic occurrence which might be related to
olygenic model and environmental modiﬁcations.14 Soo-Kyung
oh reported a case of quadruple malignancy involving ovary and
ndometrium, but after breast and rectal cancer.15
The diagnostic criteria for multiple primary cancers were advo-
ated by Warren and Gates in 1932, namely: (1) Each cancer must
e deﬁnitively malignant by histopathology, (2) they must be his-
ologically different, and (3) the possibility of metastasis among
he cancers must be excluded.16 Our patient fulﬁlled these criteria
nd classiﬁed as metachronous MPM.  Metachronous MPM  includ-
ng adenocarcinoma of small intestine, inﬁltrating duct carcinoma
f breast and papillary adenocarcinoma of ovary has not been
eported among Indians. Our patient underwent three surgical pro-
edures and received 16 different cycles of chemotherapy as her
eneral condition was good. But choice of chemotherapeutic agents
nd regimens was difﬁcult task.PEN  ACCESS
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While  managing patients of malignancies, risk of developing
subsequent malignant lesions of higher order should be always be
kept in mind. We  learnt from present case that clinician should
not only think of recurrence or metastatic lesion during follow up
period, but also occurrence of second or higher primary lesions in
cancer survivors. This high risk population should be targeted for
preventive and interventional strategies.
Challenges faced in management of this case were due to dif-
ferential diagnosis, difﬁculty to distinguish between local, distant
metastasis, recurrences and diagnosis of onset of new malig-
nant lesion with different histopathology. Aggressive diagnostic
approach of a surgeon may  overcome these challenges. There are
no standard guidelines for management of MPM  but type of malig-
nancies, progression of disease, response to therapy and general
condition of patients should be always taken into consideration. If
primary lesion is curative, clinician should opt for radical therapy
otherwise palliative treatment should be considered.
4. Conclusion
Whenever a patient with known malignancy complains of new
symptom we tend to correlate it with recurrence of primary one.
But one should always keep in mind the possibility of subsequent
new malignancy. As a clinician one should always have high index
of suspicion for MPM  for early detection with improved outcome.
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